Takeda
Takeda pays $1,2 billion to Innovent for two cancer projects
ASCO 2025: Takeda presents new results for rusfertide
Bioteknik
Takeda's milestone payment strengthens BioInvent's business model
BioInvent strengthens its position as a partner in antibody development....
News roundup Wednesday April 9
Takeda
BioInvent expects a continued news-rich 2024
With a cash position of over one billion SEK...
News roundup Wednesday July 31
Diamyd Medical
Alzinova receives positive feedback from independent expert group
After receiving an independent positive safety review...
Strong investment and product development in Toleranzia's focus area myasthenia gravis
Toleranzia was recently recognized in connection with the successful...
QuiaPEG conducts share issue for development and partnership
Drug delivery company QuiaPEG Pharmaceuticals is developing improved drugs against...
QuiaPEG CEO on out-licensing and partnerships
Drug delivery company QuiaPEG is developing improved versions of already...
Intervju
CMO provides insight into new BioInvent collaboration
From achieving a strong ownership base, a...
Intervju
News roundup Tuesday, January 17
The latest from BioStock